ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
Key Highlights
- ➤ARR-002 first patient dosed in U.S. Phase 1 trial for ovarian and endometrial cancer
- ➤ArriVent advances second ADC into clinical development
- ➤ARR-002 targets MUC16 and NaPi2b with a tetravalent 2+2 format
- ➤ArriVent licensed ARR-002 development and commercialization rights in Greater China to Allist
Expert Statements
Stuart Lutzker, President of Research and Development at ArriVent
“We are pleased to have dosed our first patient with ARR-002, our second ADC from our portfolio to enter the clinic”
Stuart Lutzker, President of Research and Development at ArriVent
“Both MUC16 and NaPi2b are highly over-expressed in ovarian and endometrial cancer, and the dual targeting approach of ARR-002 is designed to overcome a key limitation of single-target ADCs in solid tumors where target expression can be heterogenous and can limit effective payload delivery to all tumor cells.”
Stuart Lutzker, President of Research and Development at ArriVent
“The entry of ARR-002 into the clinic for ovarian and endometrial cancer broadens our clinical pipeline beyond lung and gastrointestinal cancers, where we also have active programs.”
NEWTOWN SQUARE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it dosed its first patient in the Phase 1 trial in the U.S. with ARR-002 (NCT07755436), a potential first-in-class MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate (ADC) for ovarian and endometrial cancer.
“We are pleased to have dosed our first patient with ARR-002, our second ADC from our portfolio to enter the clinic,” said Stuart Lutzker, MD, Ph.D., President of Research and Development at ArriVent. “Both MUC16 and NaPi2b are highly over-expressed in ovarian and endometrial cancer, and the dual targeting approach of ARR-002 is designed to overcome a key limitation of single-target ADCs in solid tumors where target expression can be heterogenous and can limit effective payload delivery to all tumor cells.”
Get started
Create a free account to read the full story.